SCHEMBL1172089

SCHEMBL1172089

COc1ccc(C2(N)N=C(N)C=CN2)cc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BACE1 P56817 4/20 0.39
TDP1 Q9NUW8 2/20 0.38
MAPK1 P28482 1/20 0.38
CYP3A4 P08684 2/20 0.37
ALDH1A1 P00352 1/20 0.37
BACE2 Q9Y5Z0 1/20 0.37
MAOB P27338 2/20 0.37
MAOA P21397 1/20 0.37
NR4A1 P22736 1/20 0.36
CA12 O43570 1/20 0.35
CA1 P00915 1/20 0.35
CA2 P00918 1/20 0.35
CA7 P43166 1/20 0.35
CA9 Q16790 1/20 0.35
CA14 Q9ULX7 1/20 0.35
ALOX15 P16050 1/20 0.35
CTSE P14091 1/20 0.35
CYP2C19 P33261 1/20 0.35
MAPT P10636 1/20 0.34
KDM4E B2RXH2 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1171878 0.84 ALDH1A1 (0.35) ALDH1A1MAPT
SCHEMBL1171937 0.83 TSHR (0.43) BACE1TDP1ALDH1A1BACE2CA12
SCHEMBL1172013 0.82 BACE1 (0.42) BACE1CYP3A4ALDH1A1BACE2CTSE
SCHEMBL1171801 0.80 MAOA (0.41) BACE1TDP1ALDH1A1BACE2MAOA
SCHEMBL1171905 0.80 CTSD (0.40) BACE1BACE2KDM4E
SCHEMBL1172247 0.78 ALDH1A1 (0.41) MAPK1CYP3A4ALDH1A1CA12CA1
SCHEMBL1171769 0.78 ALDH1A1 (0.41) MAPK1CYP3A4ALDH1A1CA12CA1
SCHEMBL1172351 0.78 BACE1 (0.38) BACE1BACE2MAOBMAOA
SCHEMBL1171765 0.77 ALOX15 (0.38) TDP1MAPK1CYP3A4ALDH1A1ALOX15
SCHEMBL1171710 0.77 HSP90AA1 (0.37) BACE1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110046108-A1 PYRIMIDINE DERIVATIVES ASTRAZENECA AB (SE) 2011-02-24 US disclosed
WO-2009017838-A2 COMBINATIONS OF JAK-2 INHIBITORS AND OTHER AGENTS EXELIXIS, INC. (US) 2009-02-05 WO disclosed
EP-1981856-A2 PYRIMIDINE DERIVATIVES AstraZeneca AB (SE) 2008-10-22 EP disclosed
WO-2007085833-A2 PYRIMIDINE DERIVATIVES ASTRAZENECA AB (SE) 2007-08-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110046108-A1 PYRIMIDINE DERIVATIVES EPHB4, EPHB1, EPHB3 BACE1 3399/4885TDP1 1031/4885MAPK1 739/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.